CancerLinQ®

Are you tired of your practice's valuable data going to waste? With SmartLinQ™, you can finally harness the power of your real-world data to make positive changes in cancer care delivery. This digital solution offers interactive dashboards, reports, decision support tools, and more by analyzing your EHR data seamlessly. Whether you're a clinician, administrator, quality team member, or researcher, SmartLinQ is the ultimate platform to drive improvements in care quality, operational efficiency, research operations, and more. Say goodbye to letting your data gather virtual dust and unlock its full potential with SmartLinQ. The future of data-driven cancer care is here, and it's time to start tapping into your greatest data asset. Don't miss out on the opportunity to elevate every aspect of cancer care delivery. Request your copy of the full factsheet on SmartLinQ's robust capabilities: https://hubs.ly/Q02GmWVt0 #SmartLinQ #DataDrivenCare #CancerCareDelivery #HealthcareInnovation

Are you looking for a streamlined solution to accelerate your oncology practice's clinical trial activities? Look no further than TriaLinQ, powered by ConcertAI's Digital Trial Solutions. This single, secure, integrated platform simplifies complex trial operations, ensures compliance, and improves data collection accuracy with pre-populated fields that reduce manual data entry errors. With AI-driven technologies enhancing the clinical trial process from patient identification to data management, TriaLinQ is revolutionizing the way trials are conducted. Request to download the factsheet to learn more about how TriaLinQ can benefit your practice: https://hubs.ly/Q02FdV0v0 #clinicaltrials #oncology #AI #digitalhealth #innovation.

Let's honor the strength and courage of cancer survivors. Their inspiring stories, resilience, and fight motivate us and our work. Show support by spreading awareness, sharing love, and standing by their side. To all survivors: you are heroes. Keep fighting, keep believing, and keep inspiring us with your unwavering strength. 

Day 2 of the 2024 AACI (Association of American Cancer Institutes) Meeting is here and we are thrilled to showcase how TraiLinQ™ is revolutionizing the use of data to fill clinical trials. Visit us at table 3 to discover how our cutting-edge solutions are empowering oncologists to learn from every patient that they may reach every patient. #CRI2024 #TraiLinQ #ClinicalTrials #Oncology #Innovation

Join us today at the 2024 AACI CRI meeting for a special session from 4:00 - 4:30 pm at the Pollack Room in the Loews Hotel. This joint session, hosted by Caris Life Sciences, Thomas Jefferson University, and CancerLinQ, a ConcertAI initiative, will delve into the "Real World Application of Precision Medicine Technology to Accelerate Clinical Trials." Hope to see you there! #AACICRI #PrecisionMedicine #ClinicalTrials #HealthcareInnovation

Are you heading to the 16th Annual AACI CRI meeting in Rosemont, IL next week? Be sure to stop by table 3 to discover the cutting edge solutions that are enabling oncologists to learn from every patient that they may reach every patient. Also, learn more about our newly released TriaLinQ™ that is revolutionizing the use of data to fill clinical trials. #AACICRI24 #TriaLinQ #Oncology #HealthcareInnovation

June is a time to celebrate the vibrant and resilient LGBTQIA+ community! This month, we honor the struggles and triumphs that have shaped the fight for equality. Across the nation, June is filled with parades, protests, live theater, and countless events that highlight the richness and resilience of LGBTQIA+ culture. At ConcertAI, we proudly support our LGBTQIA+ employees and allies through our affinity group. Together, we educate, support, and raise awareness for LGBTQIA+ voices. Join us in creating a safe and inclusive environment where stories are shared, voices are heard, and connections are made. Let's continue to stand together in solidarity and love. #PrideMonth #LGBTQIA+ #Equality #CelebrateDiversity #Community

What an incredible week at the 2024 ASCO Annual Meeting! A huge thank you to everyone who visited our booth and participated in the event. It was a pleasure connecting with both old and new friends, and we are looking forward to continuing our conversations! Did you miss us at the ASCO Annual Meeting, schedule a live demo: https://hubs.ly/Q02zv_D60 #ASCO24 #Innovation #Connections #Oncology

We are having such a great last day of exhibits at the 2024 ASCO Annual Meeting! We had the privilege of hearing from Dr. Jeanny Aragon-Ching and Dr. Thomas Semrad earlier today, sharing their insights on the CancerLinQ Journey at Inova Schar Cancer Institute and Tahoe Forest Health System respectively. Curious to learn more about CancerLinQ? Visit us at booth 14013! #ASCO24 #CustomerStories #Innovation #CancerLinQJourney

We are excited to share the the results of a study that is available online in conjunction with the 2024 ASCO Annual Meeting. This study delves into the important topic of racial/ethnic disparities in locoregional second breast cancer events (SBCE) among patients with HER2-positive (HER2+) breast cancer. The findings from this study, based on the ASCO CancerLinQ Discovery (CLQD) real-world dataset, shed light on the rates of SBCE and overall survival (OS) by race and ethnicity in HER2+ breast cancer patients who received optimal versus not-optimal treatment. The results revealed some key insights: - Non-Hispanic White (NHW) patients were the most likely to present with stage I disease. - Overall, 54.2% of HER2+ BC patients received optimal treatment. - Differences in OS, but not SBCE, were observed by race/ethnicity in HER2+ BC patients. - Optimal treatment was shown to increase OS in certain patient groups. This study underscores the importance of addressing racial/ethnic disparities in breast cancer care and highlights the need for further research and interventions to ensure equitable outcomes for all patients. Come by booth 14013 today to learn more! Read the abstract: https://hubs.ly/Q02zkyPT0 #BreastCancerAwareness #HealthEquity #ASCO24 #ResearchMatters